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ORIGINAL ARTICLE VIROLOGYPatients with refractory cytomegalovirus (CMV) infection following
allogeneic haematopoietic stem cell transplantation are at high risk for
CMV disease and non-relapse mortalityJ. Liu, J. Kong, Y. J. Chang, H. Chen, Y. H. Chen, W. Han, Y. Wang, C. H. Yan, J. Z. Wang, F. R. Wang, Y. Chen,
X. H. Zhang, L. P. Xu, K. Y. Liu and X. J. Huang
Peking University People’s Hospital, Institute of Haematology, Beijing Key Laboratory of HSCT, Beijing, ChinaAbstractPre-emptive therapy is an effective approach for cytomegalovirus (CMV) control; however, refractory CMV still occurs in a considerable
group of recipients after allogeneic haematopoietic stem cell transplantation (allo-HSCT). Until now, hardly any data have been available
about the clinical characteristics and risk factors of refractory CMV, or its potential harmful impact on the clinical outcome following
allo-HSCT. We studied transplant factors affecting refractory CMV in the 100 days after allo-HSCT, and the impact of refractory CMV
on the risk of CMV disease and non-relapse mortality (NRM). We retrospectively studied 488 consecutive patients with CMV infection
after allo-HSCT. Patients with refractory CMV in the 100 days after allo-HSCT had a higher incidence of CMV disease and NRM than
those without refractory CMV (11.9% vs. 0.8% and 17.1% vs. 8.3%, respectively). Multivariate analysis showed that refractory CMV
infection in the 100 days after allo-HSCT was an independent risk factor for CMV disease (hazard ratio (HR) 10.539, 95% CI
2.467–45.015, p 0.001), and that refractory CMV infection within 60–100 days after allo-HSCT was an independent risk factor for NRM
(HR 8.435, 95% CI 1.511–47.099, p 0.015). Clinical factors impacting on the risk of refractory CMV infection included receiving
transplants from human leukocyte antigen-mismatched family donors (HR 2.012, 95% CI 1.603–2.546, p <0.001) and acute graft-versus-
host disease (HR 1.905, 95% CI 1.352–2.686, p <0.001). We conclude that patients with refractory CMV infection during the early stage
after allo-HSCT are at high risk for both CMV disease and NRM.
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E-mail: huangxiaojun@bjmu.edu.cnIntroductionViral infections remain important causes of morbidity and
mortality after allogeneic haematopoietic stem cell trans-
plantation (allo-HSCT), especially cytomegalovirus (CMV)Clinical Microbiology and Infection © 2015 European Society of Cinfection. A pre-emptive therapy approach enabled almost
complete prevention of CMV disease; however, refractory
CMV infection still developed in a subgroup of patients after
allo-HSCT [1–6]. Refractory CMV infection, which was deﬁned
as CMV infection persisting for >2 weeks in spite of standard
antivirus therapy, occurred in >40% of recipients after allo-
HSCT, leading to a prolonged medication treatment time
[1,5,7]. Until now, hardly any data have been available about the
clinical characteristics and risk factors of refractory CMV
infection, or regarding its potentially harmful impact on the
clinical outcome after allo-HSCT. It has been well documented
that clinical factors such as acute graft-versus-host diseaseClin Microbiol Infect 2015; 21: 1121.e9–1121.e15
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.06.009
TABLE 1. Patient characteristics
Characteristic All patients (n [ 488)
Age of recipients (years), median (range) 29 (2–61)
Gender: no. of patients
Male/female 280/208
Underlying disease, no. of patients
Acute myeloid leukaemia 203
Acute lymphocyte leukaemia 158
Myelodysplastic syndrome 60
Chronic myeloid leukaemia 26
Severe aplastic anaemia 26
Lymphoma 9
Myeloma 4
Fanconi anaemia/myeloﬁbrosis 1/1
Donor type, no. of patients
Matched sibling 91
Mismatched family 397
Conditioning regimen, no. of patients
BU/CY + ATG 360
TBI + CY + ATG 22
CY + ATG 8
BU + Flu + ATG 5
BU/CY 79
TBI + CY 6
TBI + Flu + CY 2
GVHD prophylaxis, no. of patients
MMF + CsA + MTX 488
Infused nuclear cells (108/kg), median (range) 7.62 (1.63–20.07)
Infused CD34+ cells (106/kg), median (range) 2.61 (0.33–84.05)
CMV-speciﬁc T-cell infusion, no. of patients 16
Donor lymphocyte infusion, no. of patients 65
Follow-up (days), median (range) 326 (34–916)
ATG, antithymocyte globulin; BU, busulfan; CMV, cytomegalovirus; CsA,
1121.e10 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMI(GVHD), donor–recipient serostatus and receiving a graft from
an unrelated donor are risk factors for CMV infection following
allo-HSCT [2,8–11]. Whether these clinical factors have an
impact on refractory CMV infection is unknown. Almyroudis
et al. [6] demonstrated that persistent CMV reactivation
occurred in 39% of T-cell-depleted haematopoietic stem cell
transplants, despite treatment with currently available antivirals,
and that the maximum CMV level was associated with persis-
tent CMV reactivation. Ljungman et al. [8] demonstrated that
the viral load kinetics after initiation of antiviral therapy were
predictive of the risk of developing CMV disease, and that, in a
group of 162 patients, the patients whose viral load decreased
more slowly in the ﬁrst week had a higher risk of CMV disease.
Beyond that, hardly any data are available about the relationship
between refractory CMV infection and CMV disease or mor-
tality. Therefore, we performed a retrospective study to anal-
yse the clinical characteristics and risk factors of refractory
CMV infection, and the effects of refractory CMV infection on
the risk of CMV disease and mortality, in a series of consecutive
allo-HSCT recipients.
cyclosporine A; CY, cyclophosphamide; Flu, ﬂudarabine; GVHD, graft-versus-host
disease; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body
irradiation.Materials and methodsPatient enrolment
Between January 2013 and July 2014, 488 patients who un-
derwent allo-HSCT from human leukocyte antigen (HLA)-
matched siblings or mismatched family donors with a
myeloablative-conditioning regimen in the Peking University
People’s Hospital, Institute of Haematology, and who experi-
enced CMV DNAemia during the ﬁrst 100 days after allo-
HSCT, were enrolled. Preliminary data showed that most of
the CMV infections (50–70%) following allo-HSCT were
identiﬁed in the ‘early’ period (<100 days) following the infusion
of the graft, and late-onset CMV infections were strongly
correlated with the early-onset cases [2,12]. Therefore, we
focused on the patients who had CMV infections during the ﬁrst
100 days after allo-HSCT. The institutional review board at the
hospital approved the protocol, and all patients or their
guardians signed consent forms approved by the institutional
review board. The patients’ characteristics are shown in
Table 1.
Transplant protocol
The donor selection and the transplant protocol were carried
out as previously reported [13–15]. Details are shown in Doc.
S1. Donor lymphocyte infusion was performed for prophylactic
or prevention purposes, according to previously reported
criteria [16,17].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectSample preparation
Before transplantation, serum samples from recipients and
donors were analysed by ELISA (Diesse, Sienna, Italy) for CMV-
speciﬁc IgG antibodies. Heparin-treated peripheral blood (PB)
was collected from the recipients weekly from day 15 to day
90, and at subsequent visits when CMV antigenaemia was
detected.
Deﬁnition
CMV infection was deﬁned as isolation of CMV virus or
detection of viral proteins or nucleic acid in any body ﬂuid or
tissue specimen. CMV DNAemia was deﬁned as the detection
of CMV DNA in samples of plasma, whole blood or isolated PB
leukocytes. Refractory CMV infection was deﬁned as CMV
DNAemia lasting for >2 weeks in spite of administration of a
full dose of antiviral drug therapy. Recurrent infection was
deﬁned as new detection of CMV infection in a patient who had
previously documented infection and in whom the virus had not
been detected for a period of at least 4 weeks during active
surveillance [1]. CMV disease was diagnosed according to
previously published criteria [1]. Other important deﬁnitions
are shown in Doc. S1.
Monitoring for CMV infection and pre-emptive therapy
CMV infection was monitored by weekly plasma CMV DNA
testing with real-time PCR (PG Biotech, Shenzhen, China). Allious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1121.e9–1121.e15
CMI Liu et al. Refractory CMV after allo-HSCT is an independent risk factor for CMV disease 1121.e11patients received prophylactic acyclovir from day 1 to day 30
and ganciclovir from day –10 to day –2. Pre-emptive therapy
with either intravenous ganciclovir or intravenous foscarnet
was given when the PCR tests were positive for >600 copies/
mL CMV in two consecutive tests or >1000 copies/mL CMV in
a single test on PB, as previous reported [18]. Treatment was
given for 2 weeks at the full dose, and as maintenance for
another 2 weeks until CMV DNA was cleared. For patients
with available CMV-speciﬁc T-cell sources, adoptive transfer of
CMV-speciﬁc T-cells was performed under the condition of
refractory CMV infection or CMV disease. CMV-speciﬁc T-cells
were generated and quality controlled in a central facility with
good manufacturing practices, as described recently [5].
Statistical analyses
Differences in categorical variables between two groups were
evaluated with the χ2 test or Fisher’s exact test. Continuous
variables were compared by use of a non-parametric test. The
association between clinical factors and refractory CMV infec-
tion, and the impact of refractory CMV infection on CMV disease
and non-relapse mortality (NRM), were analysed with Kaplan–
Meier analysis. For time-dependent variables, the proportional
hazard assumption was examined. Then, a stratiﬁed Cox model
was used to examine the effects of variables on the observation
endpoints and for testing interaction terms with covariates.
Statistical analyses were performed with IBM SPSS 19.0 statistical
software (IBM SPSS Statistics, Armonk, New York, USA).ResultsCharacteristics and clinical outcomes of recipients
Patient characteristics and clinical outcomes are shown in
Tables 1 and 2, respectively. In total, 91 patients received stem
cell grafts from matched sibling donors (MSDs), and 397 pa-
tients received grafts from HLA-mismatched donors. TheTABLE 2. Clinical outcomes
Outcome All patients (n [ 488)
Neutrophil engraftment (days), median (range) 13 (7–111)
Platelet engraftment (days), median (range) 14 (5–225)
Acute GVHD, no. of patients (%)
None 149 (30.5)
Grade I 185 (37.9)
Grade II 122 (25)
Grade III 14 (2.9)
Grade IV 18 (3.7)
Relapse, no. of patients (%) 39 (7.99)
Rrelapse time (days), median (range) 180 (56–539)
Non-relapse mortality, no. of patients (%) 60 (12.3)
Non-relapse mortality time (days), median (range) 180 (56–580)
Overall survival, no. of patients (%) 403 (82.6)
GVHD, graft-versus-host disease.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecoverall survival of patients at the end of follow-up was 82.6%,
the NRM rate was 12.3%, and the cumulative relapse rate was
7.99%.
CMV-speciﬁc T-cell transfusions were given to 16 patients.
Of these, 11 patients were diagnosed with CMV disease and the
other ﬁve with refractory CMV infection. T-cell transfusions
were given approximately 4 weeks after the start of CMV
infection, and the dose ranged from 1.9 × 104 cells/kg to
9.93 × 105 cells/kg. The therapy was effective in 12 patients,
whose CMV titre decreased rapidly. The other four patients did
not response to the cell therapy.
Refractory and recurrent CMV infection
CMV infection occurred in the recipients at a median time of 31
days (range: 6–100 days) after allo-HSCT, and the duration was
14 days (range: 1–125 days). In total, 247 (50.6%) recipients
experienced refractory CMV infection in the 100 days after
allo-HSCT. CMV was cleared at a median time of 27 days
(range: 15–125 days) in these patients. Recurrent CMV infec-
tion was observed in 148 (30.3%) of the recipients at a median
time of 90 days (range: 66–188 days) after allo-HSCT, and 110
of the patients were refractory during the ﬁrst episodes
(Table 3).
Regarding different donor type subgroups, in the patients
with MSDs, the incidence rates of refractory CMV infection and
recurrent CMV infection were 24.1% and 14.9%, whereas in the
patients with HLA-mismatched donors, the rates were 54.9%
and 31.5%, respectively.
CMV disease
CMV disease was diagnosed in 31 (6.4%) of the recipients at a
median time of 57.5 days (range: 23–260 days) after allo-HSCT.
Among these, there were 24 (77.4%) cases of pneumonia, six
(19.4%) cases of gastroenteritis, and one (3.2%) case of en-
cephalitis. CMV DNA was detected in both bronchoalveolar
lavage ﬂuid and intestinal mucosa of two patients. In one otherTABLE 3. Cytomegalovirus (CMV) infection characteristics
CMV infection
All patients
(n [ 488)
CMV DNAemia time (days after allo-HSCT), median (range) 31 (6–100)
Duration of CMV infection (days), median (range) 14 (1–125)
Refractory CMV infection, no. (%) 247 (50.6)
Duration of refractory CMV infection (days), median (range) 27 (15–125)
Recurrent CMV infection, no. (%) 148 (30.3)
Duration of tecurrent CMV infection (days after allo-HSCT),
median (range)
90 (66–188)
CMV disease, no. (%) 31 (6.4)
Pneumonia 24 (77.4)
Enteritis 6 (19.4)
Encephalitis 1 (3.2)
Duration of CMV disease (days), median (range) 57.5 (23–260)
allo-HSCT, allogeneic haematopoietic stem cell transplantation.
tious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1121.e9–1121.e15
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ﬂuid (Table 3). Nine of the patients with CMV disease suffered
NRM, and six patients died from CMV disease. The incidence
rates of CMV disease in patients with MSDs and HLA-
mismatched donors were 4.39% and 6.8%, respectively.
Clinical factors affecting refractory and recurrent CMV
infection
We analysed clinical factors that may affect refractory and
recurrent CMV infection, including patient age, sex, underlying
disease, donor age, donor type, infused mononuclear cell
number, infused CD34+ cell number, white cell engraftment,
platelet engraftment, acute GVHD, haemorrhagic cystitis,
Epstein–Barr virus infection, and donor lymphocyte infusion,
with Kaplan–Meier analysis. Factors with p-values of <0.1 were
included in the subsequent Cox multivariate analysis (Table 4).
The proportional hazard assumption was tested for time-
dependent variables such as acute GVHD, Epstein–Barr virus
infection, haemorrhagic cystitis, and hepatitis B virus infection.
The results are shown in Table S1. Stratiﬁed Cox models were
used to analyse the effects of variables on refractory CMV
infection (Table S2) The results showed that patients receivingTABLE 4. Univariate analysis of factors affecting refractory
and recurrent cytomegalovirus (CMV) infection, CMV
disease, and non-relapse mortality (NRM)
Variables
p
Refractory
CMV
infection
Recurrent
CMV
infection
CMV
disease NRM
Age of recipients (years): <30/30 0.002 0.902 0.435 0.006
Sex of recipients: male/female 0.432 0.561 0.600 0.243
Underlying disease: AML/ALL/MDS/
others
0.092 0.927 0.655 0.977
Status before allo-HSCT: CR1/CR2,
CR3, NR, relapse
0.610 0.535 0.562 0.645
Infused nuclear cells: below/equal
to or above the median
(7.62 × 108/kg)
0.719 0.079 0.856 0.435
Infused CD34+ cells: below/equal
to or above the median
(2.61 × 106/kg)
0.825 0.230 0.674 0.657
Donor type: matched sibling/
mismatched family
<0.001 <0.001 0.465 0.664
Acute GVHD
None/grade 1– IV <0.001 0.024 0.062 0.088
None, grade I/grade II– IV <0.001 0.036 <0.001 0.042
None, grade I– II/grade III– IV 0.206 0.535 <0.001 <0.001
EBV infection: without/with <0.001 0.333 0.870 0.075
Haemorrhagic cystitis: without/
with
0.035 0.045 0.073 0.069
Refractory CMV infection: without/
with
<0.001 <0.001 0.012
Recurrent CMV infection: without/
with
0.01 0.17
CMV disease: without/with <0.001
ALL, acute lymphocytic leukaemia; allo-HSCT, allogeneic haematopoietic stem cell
transplantation; AML, acute myelocytic leukaemia; CR, complete remission; EBV,
Epstein–Barr virus; GVHD, graft-versus-host disease; MDS, myeloid dysplastic
syndrome; NR, no remission.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecttransplants from HLA-mismatched donors and with acute
GVHD were at high risk for refractory CMV infection (hazard
ratio (HR) 2.012, 95% CI 1.603–2.546, p <0.001; HR 1.905,
95% CI 1.352–2.686, p <0.001) (Table 5; Fig. 1a,b).
Next, we explored the impact of refractory CMV infection
on CMV disease. In addition to the clinical factors mentioned
above, refractory CMV infection was included (Table 4). Grade
III– IV acute GVHD (HR 2.461, 95% CI 1.002–6.049, p 0.0017),
and refractory CMV infection (HR 10.539, 95% CI
2.467–45.015, p 0.001) had signiﬁcant inﬂuences on CMV dis-
ease in a stratiﬁed Cox model (Table 5; Table S2). Patients with
refractory CMV infection had an increased incidence of CMV
disease (11.9%) as compared with those without (0.8%) (p
<0.001) (Fig. 2).
The impact of refractory CMV infection on NRM was
explored in the same way. Refractory CMV infection was
considered as a time-dependent variable, and the change time
point was 60 days after allo-HSCT. This showed that refractory
CMV infection within 60 days and 100 days after allo-HSCT was
an independent risk factor for NRM (HR 8.435, 95% CI
1.511–47.099, p 0.015) (Table 5). Patients with refractory CMV
infection had an increased incidence of NRM (17.1%) as
compared with those without (8.3%) (p 0.012) (Fig. 3).
Although univariate analysis showed that both refractory
CMV infection and CMV disease had impacts on overall survival,
only CMV disease was an independent risk factor (data not
shown).
Analysis in the subgroup with HLA-mismatched donors
We explored the risk factors for refractory CMV infection and
the impact of refractory CMV infection on CMV disease andTABLE 5. Multivariate analysis of factors affecting refractory
cytomegalovirus (CMV) infection, recurrent CMV infection,
CMV disease, and non-relapse mortality
Variables HR 95% CI p
Refractory CMV infection
Donor type: matched sibling/mismatched family 2.012 1.597–2.536 <0.001
Acute GVHD: none/grade I– IV 1.717 1.102–2.675 0.017
T_COV_: t = 45 0.464 0.167–1.288 0.140
Recurrent CMV infection
Response to treatment: not refractory/refractory 3.691 2.424–5.619 <0.001
Donor type: matched sibling/mismatched family 2.457 1.585–3.807 <0.001
CMV disease
Ranking of treatment: not refractory/refractory 10.539 2.467–45.015 0.001
Acute GVHD: none, grade I– II/grade III– IV 2.461 1.002–6.049 0.017
T_COV_: t = 45 3.246 0.175–60.177 0.429
Non-relapse mortality
Ranking of treatment: not refractory/refractory 0.316 0.063–1.5759 0.160
Acute GVHD: none, grade I– II/grade III– IV 2.915 1.628–5.939 0.003
Age of recipients: below/equal to or above the
median
1.973 1.126–3.458 0.018
T_COV_: t = 60 8.435 1.511–47.099 0.015
GVHD, graft-versus-host disease; HR, hazard ratio; T_COV_, Time-dependent
covariate.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1121.e9–1121.e15
FIG. 1. Patients with acute graft-
versus-host disease (GVHD) who (a)
received transplants from mis-
matched family donors, and (b) were
at high risk for refractory cytomega-
lovirus (CMV) infection (p 0.01 and p
0.003, respectively). allo-HSCT, allo-
geneic haematopoietic stem cell
transplantation; HLA, human leuko-
cyte antigen.
CMI Liu et al. Refractory CMV after allo-HSCT is an independent risk factor for CMV disease 1121.e13NRM only in the HLA-mismatched transplant subgroup. The
outcomes were consistent with those of the whole cohort. The
only signiﬁcant risk factor for refractory CMV infection was
grade I– IV acute GVHD (HR 1.793, 95% CI 1.246–2.58, p
0.002). Patient with refractory CMV infection were at high risk
for CMV disease and NRM (HR 12.626, 95% CI 1.67–95.458, p
0.014; HR 2.066, 95% CI 1.067–4.002, p 0.031). Grade III– IV
acute GVHD also had an impact on NRM (HR 2.912, 95% CI
1.299–6.529, p 0.009).FIG. 2. Patients with refractory cytomegalovirus (CMV) infection had
an increased incidence of CMV disease (11.8%) as compared with those
without refractory CMV infection (0.8%) (p <0.001). allo-HSCT, allo-
geneic haematopoietic stem cell transplantation.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfecDiscussionAlthough refractory CMV infection occurs in a considerable
group of recipients following allo-HSCT, limited data have been
available about its clinical characteristics or risk factors, or its
relationship with the development of CMV disease and NRM.
We analysed a large cohort of patients with CMV infection after
allo-HSCT, and, for the ﬁrst time, demonstrated that refractory
CMV infection during the 100 days after allo-HSCT was an
independent risk factor for CMV disease and NRM. We also
determined that patients receiving transplants from HLA-
mismatched donors, and who showed acute GVHD, were
more susceptible to refractory CMV infection.
CMV viraemia was once a well-recognized risk factor for
CMV disease after allo-HSCT; nevertheless, pre-emptive anti-
viral therapy signiﬁcantly decreased the incidence of CMV dis-
ease. However, approximately 50% of patients with CMV
infection are refractory to the antiviral therapy [6,7,19,20].
Whether the refractory CMV infection after allo-HSCT was
correlated with the development of CMV disease and NRM was
not well explored in conjunction with pre-emptive antiviral
therapy. In this study, we found that patients with refractory
CMV infection during the ﬁrst 100 days after allo-HSCT had a
higher risk of CMV disease than those without, and that re-
fractory CMV infection was an independent risk factor for CMV
disease. In support of our results, Ljungman et al. [8] demon-
strated that the rate of response of patients to antiviral therapy
during the ﬁrst week inﬂuenced the development of CMV
disease, and that patients who responded more slowly had a
higher risk. Among T-cell-depleted allo-HSCT patients,
Almyroudis et al. [6] showed that 22% of patients with persis-
tent CMV infection developed CMV disease. We also found thattious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1121.e9–1121.e15
FIG. 3. Patients with refractory cytomegalovirus (CMV) infection had
an increased incidence of non-relapse mortality (17.1%) as compared
with those without refractory CMV infection (8.3%) (p 0.012). allo-
HSCT, allogeneic haematopoietic stem cell transplantation.
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was an independent risk factor for NRM. This might be due
to the susceptibility to CMV disease, or to toxicity caused by
prolonged antiviral medication. These results indicated that
refractory CMV infection is a severe complication in the early
period after allo-HSCT. CMV-speciﬁc T-cell transfer was per-
formed in 16 patients with refractory CMV infection, and the
clinical outcome was promising. Several studies have stated that
the infusion of low numbers of CMV-speciﬁc T-cells is safe and
effective as a treatment for refractory CMV infection and CMV
disease after allo-HSCT [5,21]. Controlled clinical trials are
needed to investigate the optimal conditions for successful
reconstitution of T-cell immunity after adoptive T-cell transfer.
In addition, studies focused on the biomarkers of refractory
CMV infection would enable early detection and make pro-
phylaxis possible.
The analysis of clinical factors that impact on refractory CMV
infection might help to identify patients at high risk. It is well
understood that patients receiving transplants from HLA-
mismatched or unrelated donors are more likely to have
CMV infection after allo-HSCT [8,22,23]. Our study demon-
strated that patients receiving transplants from HLA-
mismatched donors were also more likely to suffer from re-
fractory CMV infection than those receiving grafts from MSDs.
This might be due to the high dose and prolonged use of
immunosuppressive agents. We also demonstrated that donor
type was not a risk factor for CMV disease, in either univariateClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infector multivariate analysis. Nevertheless, as the endpoint of
observation, CMV disease occurred in only a quite small pro-
portion of this cohort, and the number of HLA-mismatched
transplants was much larger than that of matched sibling
transplants, which might have caused experimental bias and
increased the statistical variability. Enlarging the cohort or using
case pair analaysis might have decreased the bias and conﬁrmed
the results. Also, other factors, such as more active antiviral
therapy, were associated with HLA-mismatched transplants,
which might have had a positive effect in preventing CMV dis-
ease. This was supported by another study [8]; however, all of
these studies were retrospective, and further research
exploring the viral kinetics and T-cell immunity reconstitution
among patients with different donor types might shed light on
this issue. The correlation between CMV infection and acute
GVHD has been known for a long time [24]. Our data showed
that acute GVHD was an independent risk factor for refractory
CMV infection, even in the pre-emptive era.
Drug-resistant CMV infections caused by the human CMV
phosphotransferase gene (UL97) and/or the polymerase gene
(UL54) mutation were observed in 2–4% of patients with CMV
reactivation after allo-HSCT, and always with severe outcomes
[25–28]. Performing analyses of UL97 and UL54 in refractory
CMV infection might identify further drug-resistant CMV in-
fections. Monitoring these genes dynamically in refractory pa-
tients might help to demonstrate the beneﬁcial impact of their
monitoring on clinical outcome.
In conclusion, refractory CMV infection was a severe
complication following allo-HSCT, and correlated with
increased risks of CMV disease and NRM. Patients receiving
transplants from HLA-mismatched donors and who developed
acute GVHD were susceptible to refractory CMV infection.
This group of patients was refractory to traditional antiviral
drug treatment, and might need other antiviral strategies, such
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